Real-World Incidence and Determinants of Infection in Patients With Rheumatoid Arthritis Treated With Golimumab After a Median Follow-Up Time of 27 Months
Authors' conclusion
Long-term GOL treatment was associated with relatively low infection rates, most being nonserious and occurring during the first 6 months.
Study context
- Population
- Patients with rheumatoid arthritis (RA) enrolled in the Biologic Treatment Registry Across Canada (BioTRAC) initiating golimumab (GOL) treatment; mean baseline age 57.7 years, RA duration 8.0 yearsmean follow-up 27.0 months
- Participants
- 530 patients
- Outcome
- Incidence density rates of total, serious and nonserious infection
- Follow-up
- Overall (90 months) and by 6-month intervals
Methodological detailsreal-world, Canadian routine care, generalized estimating equation models, logistic regression
- Real-world
- Canadian routine care
- Generalized estimating equation models
- Logistic regression
Main finding
As reported in the abstract
Incidence density rates of infection (events per 100 person-years (PYs)) · average follow-up 27.0 months
IDR, total infections
35.1 events per 100 person-years (PYs)
IDR, nonserious infections
32.9 events per 100 PYs
IDR, serious infections
2.2 events per 100 PYs
Observational data: associations, not effects.
Further findings
Predictors of infection
- No predictors identified for infection incidence within 6 months
- Comorbid pulmonary disease associated with significantly higher odds of total and nonserious infections over time
- Higher age and high corticosteroid (CS) dose (> 5 mg/day) predicted higher odds of serious infections
GOL discontinuation
- Serious, but not nonserious, infections associated with significantly higher odds of GOL discontinuation
Original publication
Real-World Incidence and Determinants of Infection in Patients With Rheumatoid Arthritis Treated With Golimumab After a Median Follow-Up Time of 27 Months. J Rheumatol. Published 1 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →